CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 28 enrolled
Drug / intervention
Ranexa +1 moredrug
Likely dose
Ranexa 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01345188
NCT01345188Phase 4Completed
CompareCT.gov

Ranolazine in Ischemic Cardiomyopathy Patients With Persistent Chest Pain or Dyspnea Despite Conventional Therapy: A Cross-Over Study

Midwest Cardiovascular Research Foundation·interventional·Posted Apr 29, 2011·Updated Dec 9, 2024

In Brief

A Phase 4 clinical trial evaluating Ranexa and Placebo for Cardiomyopathy and 2 related conditions. Completed, enrolled 28 participants across 1 site.

Detailed Summary

Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and shortness of breath despite conventional medical therapy and/or revascularization. The purpose of this study is to determine the efficacy of taking Ranexa versus placebo in patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional medical therapy and/or percutaneous revascularization.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiomyopathy, Chest Pain, Dyspnea
CountriesUnited States
CollaboratorsGilead Sciences

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 29, 2011
Enrollment StartApr 1, 2011
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 15.2 years ago

Interventions

Ranexadrug

1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.

Placebodrug

1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.